Author Interviews, Cannabis / 25.10.2018
Katexco Pharmaceuticals To Develop Cannabis Derivative CBD to Suppress Inflammatory Conditions
MedicalResearch.com Interview with:
Jonathan Rothbard, MA, PhD
Steinman Lab Stanford Medicine
Co-founder Gold Bee – Pharmaceutical Grade CBD Products
MedicalResearch.com: What is the background for this new company? How did Katexco get its name?
Response: Researchers with Stanford University, Jonathan Rothbard and Lawrence Steinman, formed Katexco Pharmaceuticals. Katexco will focus on developing oral therapies for inflammatory diseases based on cannabis and nicotine receptors.
Katexco will work to develop the first drug to focus on a key receptor on immune cells that are involved in inflammatory disease. The first primary target indications include gastrointestinal disorders like Crohn’s disease, gout and multiple sclerosis.
Katexco is from the Greek word to restrain or regulate, and we are trying to restrain the immune system in inflammatory disease. We produce what Observer.com has ranked the #1 CBD oil for pain. In fact, our CBD oil is the best CBD oil for pain according to more than 300 independently verified reviews from consumers on TrustSpot.
(more…)